BCIQ Profiles

Company Profile Report
0921 Roche Inflazome
BioCentury & Getty Images


Next up, NodThera? Roche’s €380M deal for Inflazome is latest NLRP3 takeout

Acquisition tops Bayer’s KaNDy buy as Europe’s largest this year

Sep 22, 2020 | 1:44 AM GMT

With its €380 million takeout of Dublin-based Inflazome, Roche is continuing the rush of pharmas targeting inflammasome companies in a deal that leaves NodThera as the last company standing among the first crop of high profile venture-backed biotechs with

Read the full 720 word article

How to gain access

Continue reading with a
two-week free trial.